Primary retroperitoneal lymph node dissection for clinical stage II seminoma
Standard
Primary retroperitoneal lymph node dissection for clinical stage II seminoma : A systematic review and meta-analysis of safety and oncological effectiveness. / Kardoust Parizi, Mehdi; Margulis, Vitaly; Bagrodia, Aditya; Bekku, Kensuke; Klemm, Jakob; Matsukawa, Akihiro; Alimohammadi, Arman; Motlagh, Reza Sari; Mostafaei, Hadi; Laukhtina, Ekaterina; Shariat, Shahrokh F.
in: UROL ONCOL-SEMIN ORI, Jahrgang 42, Nr. 4, 04.2024, S. 102-109.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Primary retroperitoneal lymph node dissection for clinical stage II seminoma
T2 - A systematic review and meta-analysis of safety and oncological effectiveness
AU - Kardoust Parizi, Mehdi
AU - Margulis, Vitaly
AU - Bagrodia, Aditya
AU - Bekku, Kensuke
AU - Klemm, Jakob
AU - Matsukawa, Akihiro
AU - Alimohammadi, Arman
AU - Motlagh, Reza Sari
AU - Mostafaei, Hadi
AU - Laukhtina, Ekaterina
AU - Shariat, Shahrokh F
N1 - Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
PY - 2024/4
Y1 - 2024/4
N2 - To evaluate the oncological outcomes and safety of primary retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) II seminomatous testicular germ cell tumor (TGCT). A literature search using PubMed, Scopus, and Cochrane Library was conducted on July 2023 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis (PRISMA) guidelines. The pooled recurrence rate and treatment-related complications were calculated using a random effects model. Overall 8 studies published between 1997 and 2023 including a total of 355 patients were selected for systematic review and meta-analysis with the overall median follow-up of 38 months. The overall and infield recurrence rate were 0.14 (95% CI: 0.08-0.22) and 0.04 (95% CI: 0.00-0.11), respectively. The overall pooled rate of ≥ Clavien Dindo grade III complications was 0.04 (95% CI: 0.01-0.10); there was no significant heterogeneity (I^2 = 35.10%, P = 0.19). Antegrade ejaculation was preserved with the overall pooled rate of 0.98 (95% CI: 0.95-1.00); there was no significant heterogeneity on Chi-square and I2 tests (I^2 = 0.00%, P = 0.58). Primary RPLND is a safe and effective treatment option for patients with CS II seminomatous TGCT resulting highly promising cure rates combined with low treatment-associated adverse events, at medium-term follow-up. However, owing to the lack of comparative studies to the current standard of care and the limited follow-up, individual decision must be made with the informed patient in a shared decision process together with a multidisciplinary team.
AB - To evaluate the oncological outcomes and safety of primary retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) II seminomatous testicular germ cell tumor (TGCT). A literature search using PubMed, Scopus, and Cochrane Library was conducted on July 2023 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis (PRISMA) guidelines. The pooled recurrence rate and treatment-related complications were calculated using a random effects model. Overall 8 studies published between 1997 and 2023 including a total of 355 patients were selected for systematic review and meta-analysis with the overall median follow-up of 38 months. The overall and infield recurrence rate were 0.14 (95% CI: 0.08-0.22) and 0.04 (95% CI: 0.00-0.11), respectively. The overall pooled rate of ≥ Clavien Dindo grade III complications was 0.04 (95% CI: 0.01-0.10); there was no significant heterogeneity (I^2 = 35.10%, P = 0.19). Antegrade ejaculation was preserved with the overall pooled rate of 0.98 (95% CI: 0.95-1.00); there was no significant heterogeneity on Chi-square and I2 tests (I^2 = 0.00%, P = 0.58). Primary RPLND is a safe and effective treatment option for patients with CS II seminomatous TGCT resulting highly promising cure rates combined with low treatment-associated adverse events, at medium-term follow-up. However, owing to the lack of comparative studies to the current standard of care and the limited follow-up, individual decision must be made with the informed patient in a shared decision process together with a multidisciplinary team.
KW - Male
KW - Humans
KW - Seminoma/pathology
KW - Retroperitoneal Space/pathology
KW - Neoplasms, Germ Cell and Embryonal/surgery
KW - Lymph Node Excision/adverse effects
KW - Testicular Neoplasms/pathology
KW - Treatment Outcome
KW - Retrospective Studies
KW - Neoplasm Staging
U2 - 10.1016/j.urolonc.2024.01.014
DO - 10.1016/j.urolonc.2024.01.014
M3 - SCORING: Review article
C2 - 38360519
VL - 42
SP - 102
EP - 109
JO - UROL ONCOL-SEMIN ORI
JF - UROL ONCOL-SEMIN ORI
SN - 1078-1439
IS - 4
ER -
